Advancing Medicinal Chemistry Through FMO: Sygnature's Platform.

The FMO Sygnature Platform (FMO-SP) transforms the fragment molecular orbital method (FMO) into a practical framework for drug discovery by combining quantum-level accuracy with workflow automation and intuitive visualization. FMO-SP quantifies residue-level stabilizing and destabilizing interactions, including solvation and polarisation effects, that are often missed by classical force fields. Three showcases illustrate its broad applicability. In kinase design (p38α MAPK), integration with nonequilibrium simulation/molecular dynamics (NES/MD) linked energetic magnitude with dynamic persistence, distinguishing consistent hot spots from transient interactions and informing strategies for potency. In safety pharmacology, application to the hERG potassium channel revealed how burial of a ligand's basic center within the channel's negative electrostatic field drives blockade, highlighting pKₐ reduction as a rational approach to mitigate cardiotoxicity. In metabolic GPCRs (GLP-1R), analysis of Danuglipron demonstrated how electrostatic anchors and hydrophobic reinforcement explain potency trends, guiding next-generation oral agonist design. Beyond protein-ligand systems, FMO-SP extends to PPIs, ADCs, Molecular Glue Degraders (MGDs), PROTACs, and RNA-ligand complexes, and ongoing integration with AI pipelines promises scalable and interpretable hybrid approaches. Together, these advances establish FMO-SP as a practical quantum-based platform that delivers actionable insights to accelerate medicinal chemistry optimization.